These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 3279496)

  • 21. Comparative evaluation of ciprofloxacin, enoxacin, and ofloxacin in experimental Pseudomonas aeruginosa pneumonia.
    Kemmerich B; Small GJ; Pennington JE
    Antimicrob Agents Chemother; 1986 Mar; 29(3):395-9. PubMed ID: 2940970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of quinolones in staphylococcal infection.
    Shah PM
    J Chemother; 1989 Aug; 1(4):253-6. PubMed ID: 2809692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The adverse effects of fluoroquinolones.
    Smith CR
    J Antimicrob Chemother; 1987 Jun; 19(6):709-11. PubMed ID: 3475267
    [No Abstract]   [Full Text] [Related]  

  • 24. The use of quinolones in respiratory tract infections.
    Maesen FP; Davies BI; Geraedts WH; Baur C
    Drugs; 1987; 34 Suppl 1():74-9. PubMed ID: 3325259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A review on the impact of 4-quinolones on the normal oropharyngeal and intestinal human microflora.
    Edlund C; Nord CE
    Infection; 1988; 16(1):8-12. PubMed ID: 3283041
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative in vitro studies with 4-quinolone antimicrobials.
    Felmingham D; O'Hare MD; Robbins MJ; Wall RA; Williams AH; Cremer AW; Ridgway GL; Grüneberg RN
    Drugs Exp Clin Res; 1985; 11(5):317-29. PubMed ID: 2941259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemotherapeutic effects of ofloxacin (HOE 280) and other quinolone-carboxylic derivates in the treatment of experimental lung infections due to Klebsiella pneumoniae DT-S in mice.
    Klesel N; Limbert M; Seibert G; Winkler I; Schrinner E
    Infection; 1986; 14 Suppl 1():S36-9. PubMed ID: 2937738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro and in vivo activity of NY-198, a new difluorinated quinolone.
    Hirose T; Okezaki E; Kato H; Ito Y; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1987 Jun; 31(6):854-9. PubMed ID: 3476021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In-vitro activity of newer quinolones against aerobic bacteria.
    Auckenthaler R; Michéa-Hamzehpour M; Pechère JC
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():29-39. PubMed ID: 2940214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
    King A; Phillips I
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Symposium on antimicrobial agents. The quinolones.
    Walker RC; Wright AJ
    Mayo Clin Proc; 1987 Nov; 62(11):1007-12. PubMed ID: 3312850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin.
    Wise R; Lister D; McNulty CA; Griggs D; Andrews JM
    Infection; 1986; 14 Suppl 3():S196-202. PubMed ID: 3463542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.
    Bassey CM; Baltch AL; Smith RP
    J Antimicrob Chemother; 1986 May; 17(5):623-8. PubMed ID: 2941401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative in-vitro activity of five fluoroquinolones against mycobacteria.
    Davies S; Sparham PD; Spencer RC
    J Antimicrob Chemother; 1987 May; 19(5):605-9. PubMed ID: 3112094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical pharmacokinetics of the newer antibacterial 4-quinolones.
    Neuman M
    Clin Pharmacokinet; 1988 Feb; 14(2):96-121. PubMed ID: 3282749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Respiratory infections: clinical experiences with the new quinolones.
    Davies BI; Maesen FP
    Pharm Weekbl Sci; 1987 Dec; 9 Suppl():S53-7. PubMed ID: 3438151
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia.
    Thys JP; Jacobs F; Byl B
    Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):304-15. PubMed ID: 1864291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of ciprofloxacin.
    Bergan T; Dalhoff A; Rohwedder R
    Infection; 1988; 16 Suppl 1():S3-13. PubMed ID: 3286512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Place of quinolones in the therapeutic armoury.
    Van Klingeren B
    Pharm Weekbl Sci; 1986 Feb; 8(1):40-1. PubMed ID: 3960692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of fluoroquinolones in the management of skin, soft tissue, and bone infections.
    Fong IW
    Clin Invest Med; 1989 Feb; 12(1):44-9. PubMed ID: 2646054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.